abpi and our regional industry groups karen thomas
TRANSCRIPT
ABPI and our Regional Industry GroupsKaren Thomas, Regional Partnership Manager London | ABPI
Focus for the day
• The ABPI • The background to our team• Regional Industry Group – London• Hear from our speakers• Joint working masterclass• What all this means for you
Further reading
http://www.abpi.org.uk/our-work/news/2012/Pages/140512.aspx
Real world data and e-health
ABPI landscape and policy map
Innovation, Health and Wealth
value based pricing
PPRS
Commissioning
Reputation
UK Competitiveness
NHS Partnerships
Discovery Development Approval Fair Price Access Uptake Patients
Supply ChainPartnerships for research
Animal research
EU Influence
Clinical research
Regulatory framework and MHRA
Manufacturing and the environment
Schools, higher education and skills
Intellectual property and patent
Pharmacovigilance
Patient Group Forum
Medicines Optimisation
HTA
IHW - Accelerating adoption and diffusion in the NHS
• Innovation, Health and Wealth report was published on 5th December 2011
• Sir David Nicholson also sent a letter outlining his expectations for NHS action
• ABPI warmly welcomed the report as a significant step forward to support adoption and diffusion of innovative medicines across the NHS
Our partnerships for delivery
• We have an MOU with the NHS Confederation, ABHI and Medilinks to support the implementation of Innovation, Health and Wealth
http://www.nhsconfed.org/priorities/latestnews/Pages/NHS-Confederation-joins-ABPI-ABHI-innovation-project.aspx
• This strategic agreement aims to increase the adoption and diffusion of proven technologies in areas of high clinical need to deliver high quality patient outcome and efficiency gains
• It includes showcasing best practice for joint working, judged by an independent panel – our first launch event was in February
• We work on policy at a national level with a range of organisations, including the DoH, NHS England, NICE, Royal Colleges and others
Both the NHS and pharma have their
challenges….• QIPP Challenge - £20bn in 4 years- and £50bn in future years . “Doing more with less”
• Care scandals – Mid Staffs, Winterbourne and many others - So quality needs to dramatically improve while budgets shrink – and we have just had an NHS reorganisation that’s “so big, you can see it from space”
• As for pharma – are the days of blockbusters over? R&D is getting harder, development is often through acquisition and industry is a global business. Other issues include patent expiry, changing business models, biotech companies – we work in a rapidly shifting environment
Our vision
NHS Partnerships Team established in 2012, led by Carol Blount, our director:
– Kevin Blakemore, National Manager– Regional Managers:
– Di Vegh (South)– Harriet Lewis (North)– Andy Riley (Mids and East)– Karen Thomas (London)
– Mike Ringe, Therapy Group Manager– Terry Harrison, consultant– Industry secondee
currently Farid Bidgoli from AZ
Industry as an integral part of the NHS’s solution to the delivery of better patient outcomes
NHS Partnership team priorities
We are:- Identifying and sharing local NHS issues, organisational and policy changes with member companies- Taking the lead on themes from the Innovation, Health and Wealth and other key priorities, e.g. medicines optimisation- Demonstrating the value of medicines as an opportunity to improve outcomes rather than as a cost pressure to commissioners and providers- Supporting companies in the development of Joint Working projects
We aren’t: - Promoting a particular company/ therapy area or product- Trying to improve your market share- Replicating or ‘competing’ with member company field teams- The only way that the NHS can engage with pharma
1. Wide range of transformational skills, knowledge and experience of Pharma and the new NHS
2. Brokerage to help Pharma and NHS relationships and improve the environment for business to business interaction and shared learning
3. Identifying opportunities and 'partnerships' that involves a mutually beneficial transaction between industry, NHS and other potential partners, that in some cases, an individual company would not be privy to.
4. Understand the barriers to access and what enablers can be used to break these down to bring parties together
5. Experts in the use of the “7 step partnership model” and how it should be used to enable openness & transparency
10
The Partnership team’s USP
Regional Industry Groups• Summer 2012, we wrote to all member company GMs, asking for nominations to sit on our Regional Industry Groups = RIGs
• Individuals had to have at least 5+ years of market access experience at a senior level, and be prepared to take an industry perspective
• The ABPI funds these groups – they are not ‘pay to play’
• Each region was allocated 12 – 15 places and the first meeting took place in the South in November 2012
• We elected a Chair – Stephen Fensome, Almirall – and a deputy Chair – Nick Jones
• The ABPI Regional Manager organises all the meetings and provides secretariat
Joint working in London ?
Quotes on Joint Working
I am appalled when reps come to see me and are ill prepared and don’t do their research . All the
information is in the public domain.
Chief Pharmacist, secondary care
“JW with governance –
fantastic! This is exactly what is
needed.” – Lead Pharmacist, primary care
We want industry to get involved in the projects at the embryonic stage. We
want a long-term sustainable relationship.” - Consultant secondary
care
“I wish this JW criteria existed before. It makes
the NHS feel safer working with industry, especially as the ABPI
is endorsing it.” – Governance Manager
secondary care
“Why doesn’t pharma just provide sponsorship and let
the NHS do the rest?” – Primary
Care lead
“I’m interested in JW, but what does
industry have to offer?” –
Innovation Lead secondary care
“It’s disappointing when pharma
provides financial resources but no other resource.” –
Governance Manager secondary care
“The CCGs are gagging for JW with industry, but it has to
be open & transparent.” – Lead Pharmacist, primary
care
“NHS is wary to work with pharma, so you have to sell the concept of JW.” – Pharmaceutical Advisor primary
care
Thank you & enjoy your meeting